Details for New Drug Application (NDA): 204144
✉ Email this page to a colleague
NDA 204144 describes SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, which is a drug marketed by Ph Health and Sandoz and is included in two NDAs. It is available from one supplier. Additional details are available on the SITAGLIPTIN AND METFORMIN HYDROCHLORIDE profile page.
The generic ingredient in SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
The generic ingredient in SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
Summary for 204144
| Tradename: | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Applicant: | Ph Health |
| Ingredient: | metformin hydrochloride; sitagliptin phosphate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG;EQ 50MG BASE | ||||
| Approval Date: | Jun 4, 2025 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 50MG BASE | ||||
| Approval Date: | Jun 4, 2025 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 100MG BASE | ||||
| Approval Date: | Jun 4, 2025 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
